Lidco Group, the cardiovascular monitoring company, announced today that its LiDCOrapid Monitor has been featured in a case study from Intel, world leader in silicon chip innovation. The trial is reported to be the largest of its kind in the world to date.
The AIM-listed LiDCO group was established in 1991 by Dr Terry O'Brien, Dr David Band, Dr Robert Linton and Dr Jiri Kratochvil in collaboration with the United Dental and Medical Schools of St Thomas' and Guys Hospitals (now King's College, London.) Since that time, the Group has specialised in cardiovascular monitoring.
The LiDCOrapid Monitor uses Intel’s processing chips within terminals provided by Advantech to provide physicians with information on the patient’s fluid and cardiovascular status during surgery or while in intensive care. According the the announcement, these monitors are fully compliant with all medical related technology standards, and ‘lead the way in terms of display, performance and power consumption’.
Users of the new technology include OPTIMISE, a government-supported multi-centre trial in the UK, which aims to improve surgical outcomes by optimising patient's cardiovascular management.
Dr Terry O'Brien, CEO of LiDCO, commented:
"I am delighted that Intel has recognised LiDCO as an innovative and leading technology developer in the medical sector. We place a high emphasis on performance and quality; our ongoing relationship with Intel and Advantech allow us to deliver cutting edge technology cost effectively. To be acknowledged in this case study for our innovation and having the product of that collaboration, the LiDCOrapid, chosen as the sole technology for the OPTIMISE study is a great honour for us."
The case study is available on Intel's website.
